Evidence map›Paper›PMID 37237391›Full record

ArticleMicrobiome2023

Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection.

Zheng Wang, Brandilyn A Peters, MacKenzie Bryant, David B Hanna, Tara Schwartz, Tao Wang, Christopher C Sollecito, Mykhaylo Usyk, Evan Grassi, Fanua Wiek and 16 more

Registry-linked trialOpen access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06513026 (Milk for Diabetes Prevention), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06513026 narecruitingnot on this mapstarted 2026, after this paper: background citation

Milk for Diabetes Prevention

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2026 to 2028Enrolled40ConditionsLactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-DiabetesArmsLactose-Containing Milk, Lactose-Free Milk
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 1 country.

Zheng WangDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Brandilyn A PetersDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
MacKenzie BryantDepartment of Pediatrics, University of California, La Jolla, San Diego, CA, USA.
David B HannaDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Tara SchwartzDepartment of Pediatrics, University of California, La Jolla, San Diego, CA, USA.
Tao WangDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Christopher C SollecitoDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.
Mykhaylo UsykDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.
Evan GrassiDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.
Fanua WiekDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.
Lauren St PeterDepartment of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.
Wendy S PostDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Alan L LandayDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Howard N HodisAtherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Kathleen M WeberHektoen Institute of Medicine, Chicago, IL, USA.
Audrey FrenchDepartment of Internal Medicine, Stroger Hospital of Cook County, Chicago, IL, USA.
Elizabeth T GolubDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jason LazarDepartment of Medicine, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA.
Deborah GustafsonDepartment of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Kathryn AnastosDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Clary B ClishBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Robert D BurkDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Robert C KaplanDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Rob KnightDepartment of Pediatrics, University of California, La Jolla, San Diego, CA, USA.
Qibin QiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA. qibin.qi@einsteinmed.edu.
Albert Einstein College of Medicine · USUniversity of California, San Diego · USJohns Hopkins University · USBroad Institute · USFred Hutch Cancer Center · USHektoen Institute · USJohn H. Stroger, Jr. Hospital of Cook County · USRush University Medical Center · USState University of New York · USSUNY Downstate Health Sciences University · USUniversity of Southern California · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NCI NIH HHS P30 CA013330NHLBI NIH HHS K01 HL129892NHLBI NIH HHS K01 HL137557NHLBI NIH HHS K01 HL160146NHLBI NIH HHS R01 HL083760NHLBI NIH HHS R01 HL095140NHLBI NIH HHS R01 HL126543NHLBI NIH HHS R01 HL132794NHLBI NIH HHS R01 HL140976NHLBI NIH HHS R01HL140976NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI124414NIAID NIH HHS U01 AI035004NIDDK NIH HHS P30 DK040561NIMHD NIH HHS R01 MD011389NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

backgroundAlterations in gut microbiota have been implicated in HIV infection and cardiovascular disease. However, how gut microbial alterations relate to host inflammation and metabolite profiles, and their relationships with atherosclerosis, have not been well-studied, especially in the context of HIV infection. Here, we examined associations of gut microbial species and functional components measured by shotgun metagenomics with carotid artery plaque assessed by B-mode carotid artery ultrasound in 320 women with or at high risk of HIV (65% HIV +) from the Women's Interagency HIV Study. We further integrated plaque-associated microbial features with serum proteomics (74 inflammatory markers measured by the proximity extension assay) and plasma metabolomics (378 metabolites measured by liquid chromatography tandem mass spectrometry) in relation to carotid artery plaque in up to 433 women.

resultsFusobacterium nucleatum, a potentially pathogenic bacteria, was positively associated with carotid artery plaque, while five microbial species (Roseburia hominis, Roseburia inulinivorans, Johnsonella ignava, Odoribacter splanchnicus, Clostridium saccharolyticum) were inversely associated with plaque. Results were consistent between women with and without HIV. Fusobacterium nucleatum was positively associated with several serum proteomic inflammatory markers (e.g., CXCL9), and the other plaque-related species were inversely associated with proteomic inflammatory markers (e.g., CX3CL1). These microbial-associated proteomic inflammatory markers were also positively associated with plaque. Associations between bacterial species (especially Fusobacterium nucleatum) and plaque were attenuated after further adjustment for proteomic inflammatory markers. Plaque-associated species were correlated with several plasma metabolites, including the microbial metabolite imidazole-propionate (ImP), which was positively associated with plaque and several pro-inflammatory markers. Further analysis identified additional bacterial species and bacterial hutH gene (encoding enzyme histidine ammonia-lyase in ImP production) associated with plasma ImP levels. A gut microbiota score based on these ImP-associated species was positively associated with plaque and several pro-inflammatory markers.

conclusionAmong women living with or at risk of HIV, we identified several gut bacterial species and a microbial metabolite ImP associated with carotid artery atherosclerosis, which might be related to host immune activation and inflammation. Video Abstract.

Indexed as

AtherosclerosisCarotid Artery DiseasesCarotid StenosisGastrointestinal MicrobiomeHIV InfectionsBiomarkersCarotid ArteriesFemaleHumansInflammationProteomicsBiomarkersAtherosclerosisGut microbiotaHIV infectionInflammatory markersMetabolomics

Identifiers

PMID37237391
PMCPMC10224225
OpenAlexW4378515736

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.